If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
297
results.
Updated on
15/11/2026 [07:34:00]
Results 150 to 175 of 297
Absstract of: US20260284023A1
Methods of use of CFTR corrector compounds, particularly lumacaftor and tezacaftor, to treat reduced cerebral perfusion associated with heart failure, sudden sensoneurinal hearing loss, vascular dementia, arterial hypertension, ischemic stroke, hemorrhagic stroke, heart disease, diabetes and Alzheimer's disease by treatment with an amount sufficient to provide a proteostatic effect on cystic fibrosis transmembrane conductance regulator (CFTR) protein expression in cerebral artery smooth muscle cells and an increase in cerebrovascular perfusion in the patient.
Absstract of: MX2026005980A
The invention provides compositions and methods for the treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient, such as Alzheimer's Disease. Such methods entail administering a pharmaceutical composition comprising an immunogenic fragment of Aβ capable of inducing a beneficial immune response in the form of antibodies to Aβ. The immunogenic fragments comprise linear or multivalent peptides of Aβ. Pharmaceutical compositions comprise the immunogenic fragment chemically linked to a carrier molecule which may be administered with an adjuvant.
Absstract of: EP4810493A1
The present invention relates to a heterocyclic carbonyl derivative modulator, a preparation method therefor, and the use thereof. Specifically, the present invention relates to a compound represented by general formula (II-B), a preparation method therefor, a pharmaceutical composition containing said compound, and a use thereof as a modulator in the treatment of Alzheimer's disease, schizophrenia, pain, addiction, and sleep disorders, wherein each substituent in general formula (II-B) is as defined in the description.
Absstract of: WO2025104230A1
The present disclosure relates to compounds that are IL-17A modulators. The compounds have the structural Formula I defined herein. The present disclosure also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of diseases or disorders associated with modulation of IL-17A activity.
Absstract of: US20250152747A1
0000 Provided herein are expression cassettes for expressing a transgene in a cell, wherein the transgene encodes a GCase polypeptide. Also provided are methods to treat Gaucher Disease or GBA-PD. Further provided herein are vectors (e.g., rAAV vectors), viral particles, pharmaceutical compositions, and kits for expressing an GCase polypeptide in an individual in need thereof.
Absstract of: CA3319461A1
The present invention provides a novel Kv1.3 channel (or Kv1.3) inhibitor, which can be used for preventing and/or treating Kv1.3 channel (or Kv1.3)-related diseases, including immune and inflammatory diseases, such as multiple sclerosis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, rheumatoid arthritis, type I diabetes, psoriasis and asthma, spondylitis and periodontitis; and obesity, type 2 diabetes, renal fibrosis, Alzheimer's disease, and ischemic stroke.
Absstract of: CA3319211A1
A compound specifically binding to an -synuclein aggregate, and a preparation method therefor and the use thereof. Specifically, the compound binding to the α-synuclein aggregate comprises compounds as shown in formula A or sub-general formulas thereof, or stereoisomers, pharmaceutically acceptable salts, solvates or stable isotope variants thereof. The compound is a small molecule tracer, which can specifically recognize the α-synuclein aggregate, and can be used for the preparation of a drug for the treatment or diagnosis of neurodegenerative diseases (such as Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, Alzheimer's disease, amyotrophic lateral sclerosis, progressive supranuclear palsy and progressive muscular atrophy) related to the -synuclein aggregate and other misfolded proteins.
Absstract of: US20260272856A1
This disclosure relates to administration of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg or less of bupropion hydrochloride, or a molar equivalent amount of the free base form or another salt form of bupropion; and 2) about 40-50 mg, about 44-46 mg, or about 45 mg or less of dextromethorphan hydrobromide, or a molar equivalent amount of the free base form or another salt form of dextromethorphan in human patients for treating neurological and psychiatric conditions, such as agitation associated Alzheimer's disease and/or reducing relapse of agitation in Alzheimer's disease.
Absstract of: US20260275352A1
The present disclosure relates to AAVs encoding a SOD1 targeting polynucleotide which may be used to treat amyotrophic lateral sclerosis (ALS) and delivery methods for the treatment of spinal cord related disorders including ALS.
Absstract of: WO2026193281A1
Provided herein are compositions and methods for reducing expression of RBM39 and for treating diseases and/or conditions characterized by increased expression of RBM39 (e.g., a cancer) in subjects in need thereof, by administering compositions comprising compounds described herein. Also provided herein are compositions and methods for reducing expression of MSH3 and for treating diseases and/or conditions characterized by increased expression of MSH3 (e.g., Huntington's Disease) in subjects in need thereof, by administering compositions comprising compounds described herein.
Absstract of: WO2026192853A1
The present disclosure provides pharmaceutical compositions and methods for the treatment, delaying progression and prevention of degenerative cognitive disorders such as Alzheimer's disease (AD) and its variations. There are also provided methods of treating AD in human subject by reducing amyloid pathology and improving synaptic integrity.
Absstract of: WO2026190230A1
The present invention relates to alpha-synuclein antibodies which are useful in diagnostic assays for detecting aggregates, oligomers and fibrillar forms of alpha- synuclein in patient samples. These antibodies enable diagnosis and efficient treatment of alpha-synucleinopathies such as Parkinson's Disease (PD) or Multiple System Atrophy (MSA) patients by assessing and monitoring the pathological alpha-synuclein levels in patients.
Absstract of: AU2025225323A1
The present invention relates to a solid composition, and its use in the treatment of Parkinson's disease, comprising at least two compartments, a first active pharmaceutical ingredient (API) and a second API, preferably for increasing uptake of the second API thereby optimizing its use in the treatment of Parkinson's disease, in particular improving its clinical activity and reducing its side effects associated with the treatment of Parkinson's disease.
Absstract of: US20260275351A1
Described are RNAi agents, compositions that include RNAi agents, and methods for inhibition of a Superoxide Dismutase 1 (SOD1) gene. The SOD1 RNAi agents and RNAi agent conjugates disclosed herein inhibit the expression of an SOD1 gene. Pharmaceutical compositions that include one or more SOD1 RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the described SOD1 RNAi agents to central nervous system (CNS) tissue, in vivo, provides for inhibition of SOD1 gene expression and a reduction in SOD1 activity, which can provide a therapeutic benefit to subjects, including human subjects, for the treatment of various diseases including amyotrophic lateral sclerosis (ALS).
Absstract of: WO2026189517A1
Disclosure herein Mirtazapine for use in treating bulbar-onset ALS (amyotrophic lateral sclerosis), and kit comprising Mirtazapine for treating bulbar-onset ALS. Also disclosed herein a method for treating bulbar-onset ALS comprising administration of Mirtazapine, optionally with an additional therapy for treating ALS.
Absstract of: US20260272976A1
Described herein are methods of monitoring and treating a subject with ALS based on biomarkers.
Absstract of: AU2026226429A1
An effective amount of quercetin, vitamin B3, vitamin C, zafirlukast and optionally folic acid for use in treating amyotrophic lateral sclerosis in a subject. Also disclosed are said combination for use in reducing, slowing or abating the progression of amyotrophic lateral sclerosis or a symptom thereof. ep e p
Absstract of: US20260275333A1
Disclosed herein are oligonucleotides with one or more spacers or without a spacer. In various embodiments, STMN2, KCNQ2, UNC13A, or SMN2 oligonucleotides with spacer(s) reduce STMN2 transcripts with cryptic exons or reduce mis-spliced KCNQ2, UNC13A, or SMN2 transcripts and increase full length STMN2, KCNQ2, UNC13A, SMN transcripts, thereby imparting therapeutic efficacy against neurological diseases such as amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), Alzheimer's disease (AD) or spinal muscular atrophy (SMA).
Absstract of: US20260274931A1
Disclosed herein are methods of conducting clinical trials in Alzheimer's disease (AD). Methods of selecting a medicament and treating an AD subject are disclosed. Methods, systems, kits, and devices for selecting a subject in AD clinical trials and treatment protocols are disclosed herein.
Absstract of: WO2026189377A1
Provided is use of an RIPK1 inhibitor in the treatment of Alzheimer's disease. Specifically, provided is a potential treatment method for Alzheimer's disease. The method uses the RIPK1 inhibitor to ameliorate and inhibit brain inflammation and the development of Alzheimer's disease caused by changes in the activity or expression level of myeloid INPP5D or RIPK1 activation, thereby ameliorating symptoms of late-onset Alzheimer's disease, especially early AD progression, and reducing brain inflammation associated with Alzheimer's disease.
Absstract of: WO2026193123A1
The present disclosure provides combinations of anti-CD3 antibodies (e.g. Foralumab), anti-amyloid therapies, and anti-tau therapies for the treatment of Alzheimer's disease.
Absstract of: US20260275314A1
The disclosure relates to compositions and methods for, inter alia, altering, e.g., enhancing, the level of GBA1 protein via delivery using an adeno-associated viral (AAV) capsid variant. The compositions and methods of the present disclosure are useful, inter alia, in the treatment of subjects who have, have been diagnosed with, or are at risk of having a GBA1-related disorder, e.g., Parkinson's Disease (PD), Gaucher Disease (GD), Parkinson's Disease Dementia (PDD), Dementia with Lewy Bodies (DLB), or Lewy Body Dementia (LBD).
Absstract of: WO2026188369A1
The present invention belongs to the technical field of biopharmaceuticals and specifically relates to use of a pharmaceutical composition in the preparation of a formulation for treating Parkinson's syndrome. Research has found that NPAFP1, NPAFP4, and NPAFP12 proteins can ameliorate the pathological features of a PD model by increasing the fluidity of α-synuclein.
Absstract of: AU2025215085A1
Disclosed herein is a compound of Formulas (I) and (II) as an FTO inhibitor with novel structures. Also disclosed herein is a pharmaceutical composition comprising the same, and a method of inhibiting weight gain, promoting weight loss, reducing serum LDL, cholesterol, LDL-c, or triglycerides, or treating obesity or an obesity-related disease (esp. obesity-related diabetes, hyperglycemia, diabetic nephropathy, hyperlipemia, coronary heart disease, atherosclerosis, hypertension, cardiovascular or cerebrovascular disease) or Alzheimer's disease by inhibiting FTO by using the compound disclosed herein.
Nº publicación: WO2026193437A1 17/09/2026
Applicant:
DIGNITY HEALTH [US]
BOARD OF TRUSTEES OF MICHIGAN STATE UNIV [US]
DIGNITY HEALTH
BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY
Absstract of: WO2026193437A1
The present disclosure provides methods and kits related to treatment of Parkinson's disease in a subject by reducing the expression of a CaV1.3 protein in a target cell by administering to the subject a therapeutically effective amount of an engineered genetic system.
BOPI
Electronic site
